{"id":1016349,"date":"2026-11-02T16:04:16","date_gmt":"2026-11-02T21:04:16","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/avalo-therapeutics-to-participate-in-upcoming-investor-conferences-7\/"},"modified":"2026-11-02T16:04:16","modified_gmt":"2026-11-02T21:04:16","slug":"avalo-therapeutics-to-participate-in-upcoming-investor-conferences-7","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/avalo-therapeutics-to-participate-in-upcoming-investor-conferences-7\/","title":{"rendered":"Avalo Therapeutics to Participate in Upcoming Investor Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p>WAYNE, Pa., Nov.  02, 2026  (GLOBE NEWSWIRE) &#8212; Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1\u03b2 pathway for immune-mediated inflammatory diseases, today announced that management will participate in the following investor conferences:<\/p>\n<p align=\"justify\">\n        <strong>Guggenheim Healthcare Innovation Conference<\/strong><br \/>\n        <br \/>Fireside Chat<br \/>November 9, 2026 at 8:30am ET<\/p>\n<p align=\"justify\">\n        <strong>Stifel 2026 Healthcare Conference<\/strong><br \/>\n        <br \/>Fireside Chat<br \/>November 10, 2026 at 2:00pm ET<\/p>\n<p>Live webcasts and replays, when available, can be found under &#8220;News \/ Events&#8221; in the Investors section of the Avalo Therapeutics website at https:\/\/ir.avalotx.com. The archived webcast will be available for replay for at least 30 days.<\/p>\n<p align=\"justify\">\n        <strong>About Avalo Therapeutics<\/strong>\n      <\/p>\n<p align=\"justify\">Avalo Therapeutics is a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1\u03b2 pathway for immune-mediated inflammatory diseases. Avalo is advancing its lead anti-IL-1\u03b2 monoclonal antibody (mAb) drug candidate, abdakibart, into a phase 3 registrational program in hidradenitis suppurativa (HS), a chronic inflammatory skin condition that affects an estimated 1-4% of the population globally. Avalo is pursuing additional development opportunities in IL-1\u03b2 driven indications. Avalo is also developing AVTX-010, a long-acting next-generation anti-IL-1\u03b2 mAb. For more information about Avalo, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=XJgpwiNEOZWoGm4D9RjGgRVtucrNxbSv7nZhcvyfXwThPG-CJ3qbrLcXNAwvLgRglRV5l2BDhCvL7A8zB9ghuQ==\" rel=\"nofollow\" target=\"_blank\">www.avalotx.com<\/a>.<\/p>\n<p>\n        <strong>For media and investor inquiries<\/strong><br \/>\n        <br \/>Jonathan Neely<br \/>VP, Head of Investor Relations<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=CrQhtZ9qavXcYi8yKEcD7kLgNixtQ1CE7kHkWyHTEdXOgoqjAlz2ibgaaRmzI4936MQms7pVHxmUKT4ySxW6Fy4CprnTm2YvMy85ofya5BQ=\" rel=\"nofollow\" target=\"_blank\">jneely@avalotx.com<\/a>\u00a0<\/p>\n<p align=\"justify\">\n        <em>or<\/em>\n      <\/p>\n<p align=\"justify\">Meru Advisors<br \/>Lauren Glaser<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=fnlhl9KBm7jfr5hY1ZtU39J4p4jALke0lU0gLtRYd531KkMeEx_l2AJK53OFnG_52GEpfFRdIYYP1Sn0UkoMNqX0UKDYRgm023Xw6CS9zf8FYZlw8cIIoB3KHuObcyfj\" rel=\"nofollow\" target=\"_blank\">lglaser@meruadvisors.com<\/a>\u00a0<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg2ODM2MCM3OTQwMzU0IzIwMTkzMjA=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZWJlN2JkNjAtZTJmNy00YTI5LWFkNzYtYjNmNTE3ZTcwYmQyLTEwMzA4OTMtMjAyNi0xMS0wMi1lbg==\/tiny\/Avalo-Therapeutics.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>WAYNE, Pa., Nov. 02, 2026 (GLOBE NEWSWIRE) &#8212; Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1\u03b2 pathway for immune-mediated inflammatory diseases, today announced that management will participate in the following investor conferences: Guggenheim Healthcare Innovation Conference Fireside ChatNovember 9, 2026 at 8:30am ET Stifel 2026 Healthcare Conference Fireside ChatNovember 10, 2026 at 2:00pm ET Live webcasts and replays, when available, can be found under &#8220;News \/ Events&#8221; in the Investors section of the Avalo Therapeutics website at https:\/\/ir.avalotx.com. The archived webcast will be available for replay for at least 30 days. About Avalo Therapeutics Avalo Therapeutics is a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1\u03b2 pathway for &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/avalo-therapeutics-to-participate-in-upcoming-investor-conferences-7\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Avalo Therapeutics to Participate in Upcoming Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1016349","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Avalo Therapeutics to Participate in Upcoming Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/avalo-therapeutics-to-participate-in-upcoming-investor-conferences-7\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Avalo Therapeutics to Participate in Upcoming Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WAYNE, Pa., Nov. 02, 2026 (GLOBE NEWSWIRE) &#8212; Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1\u03b2 pathway for immune-mediated inflammatory diseases, today announced that management will participate in the following investor conferences: Guggenheim Healthcare Innovation Conference Fireside ChatNovember 9, 2026 at 8:30am ET Stifel 2026 Healthcare Conference Fireside ChatNovember 10, 2026 at 2:00pm ET Live webcasts and replays, when available, can be found under &#8220;News \/ Events&#8221; in the Investors section of the Avalo Therapeutics website at https:\/\/ir.avalotx.com. The archived webcast will be available for replay for at least 30 days. About Avalo Therapeutics Avalo Therapeutics is a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1\u03b2 pathway for &hellip; Continue reading &quot;Avalo Therapeutics to Participate in Upcoming Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/avalo-therapeutics-to-participate-in-upcoming-investor-conferences-7\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-02T21:04:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg2ODM2MCM3OTQwMzU0IzIwMTkzMjA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avalo-therapeutics-to-participate-in-upcoming-investor-conferences-7\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avalo-therapeutics-to-participate-in-upcoming-investor-conferences-7\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Avalo Therapeutics to Participate in Upcoming Investor Conferences\",\"datePublished\":\"2026-11-02T21:04:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avalo-therapeutics-to-participate-in-upcoming-investor-conferences-7\\\/\"},\"wordCount\":211,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avalo-therapeutics-to-participate-in-upcoming-investor-conferences-7\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg2ODM2MCM3OTQwMzU0IzIwMTkzMjA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avalo-therapeutics-to-participate-in-upcoming-investor-conferences-7\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avalo-therapeutics-to-participate-in-upcoming-investor-conferences-7\\\/\",\"name\":\"Avalo Therapeutics to Participate in Upcoming Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avalo-therapeutics-to-participate-in-upcoming-investor-conferences-7\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avalo-therapeutics-to-participate-in-upcoming-investor-conferences-7\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg2ODM2MCM3OTQwMzU0IzIwMTkzMjA=\",\"datePublished\":\"2026-11-02T21:04:16+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avalo-therapeutics-to-participate-in-upcoming-investor-conferences-7\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avalo-therapeutics-to-participate-in-upcoming-investor-conferences-7\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avalo-therapeutics-to-participate-in-upcoming-investor-conferences-7\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg2ODM2MCM3OTQwMzU0IzIwMTkzMjA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg2ODM2MCM3OTQwMzU0IzIwMTkzMjA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/avalo-therapeutics-to-participate-in-upcoming-investor-conferences-7\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Avalo Therapeutics to Participate in Upcoming Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Avalo Therapeutics to Participate in Upcoming Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/avalo-therapeutics-to-participate-in-upcoming-investor-conferences-7\/","og_locale":"en_US","og_type":"article","og_title":"Avalo Therapeutics to Participate in Upcoming Investor Conferences - Market Newsdesk","og_description":"WAYNE, Pa., Nov. 02, 2026 (GLOBE NEWSWIRE) &#8212; Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1\u03b2 pathway for immune-mediated inflammatory diseases, today announced that management will participate in the following investor conferences: Guggenheim Healthcare Innovation Conference Fireside ChatNovember 9, 2026 at 8:30am ET Stifel 2026 Healthcare Conference Fireside ChatNovember 10, 2026 at 2:00pm ET Live webcasts and replays, when available, can be found under &#8220;News \/ Events&#8221; in the Investors section of the Avalo Therapeutics website at https:\/\/ir.avalotx.com. The archived webcast will be available for replay for at least 30 days. About Avalo Therapeutics Avalo Therapeutics is a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1\u03b2 pathway for &hellip; Continue reading \"Avalo Therapeutics to Participate in Upcoming Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/avalo-therapeutics-to-participate-in-upcoming-investor-conferences-7\/","og_site_name":"Market Newsdesk","article_published_time":"2026-11-02T21:04:16+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg2ODM2MCM3OTQwMzU0IzIwMTkzMjA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avalo-therapeutics-to-participate-in-upcoming-investor-conferences-7\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avalo-therapeutics-to-participate-in-upcoming-investor-conferences-7\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Avalo Therapeutics to Participate in Upcoming Investor Conferences","datePublished":"2026-11-02T21:04:16+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avalo-therapeutics-to-participate-in-upcoming-investor-conferences-7\/"},"wordCount":211,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avalo-therapeutics-to-participate-in-upcoming-investor-conferences-7\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg2ODM2MCM3OTQwMzU0IzIwMTkzMjA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avalo-therapeutics-to-participate-in-upcoming-investor-conferences-7\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/avalo-therapeutics-to-participate-in-upcoming-investor-conferences-7\/","name":"Avalo Therapeutics to Participate in Upcoming Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avalo-therapeutics-to-participate-in-upcoming-investor-conferences-7\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avalo-therapeutics-to-participate-in-upcoming-investor-conferences-7\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg2ODM2MCM3OTQwMzU0IzIwMTkzMjA=","datePublished":"2026-11-02T21:04:16+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avalo-therapeutics-to-participate-in-upcoming-investor-conferences-7\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/avalo-therapeutics-to-participate-in-upcoming-investor-conferences-7\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avalo-therapeutics-to-participate-in-upcoming-investor-conferences-7\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg2ODM2MCM3OTQwMzU0IzIwMTkzMjA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg2ODM2MCM3OTQwMzU0IzIwMTkzMjA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/avalo-therapeutics-to-participate-in-upcoming-investor-conferences-7\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Avalo Therapeutics to Participate in Upcoming Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1016349","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1016349"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1016349\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1016349"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1016349"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1016349"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}